Drug Profile
Research programme: trispecific antibodies - Sanofi/National Institute of Allergy and Infectious Diseases
Alternative Names: HIV trispecific antibodies - SanofiLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator National Institute of Allergy and Infectious Diseases; Sanofi
- Class Antivirals; Monoclonal antibodies; Trispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in HIV-infections in USA
- 28 Oct 2021 No recent reports of development identified for preclinical development in HIV-infections(Prevention) in USA